Articles tagged with Human Immunodeficiency Virus
The Emory University Health Sciences Center, AABB, and Red Cross will work together to reduce HIV transmission in developing countries by improving blood supply systems, testing for HIV, and creating safe transfusion centers.
A groundbreaking study by Mount Sinai School of Medicine found that the combination of Pegasysα and Copegus significantly improved treatment response rates for patients co-infected with HCV and HIV. The study showed a sustained virological response rate of 40% among all patients, with even higher efficacy rates for those with genotypes...
A combination therapy of peginterferon alfa-2a and ribavirin achieved a 40% sustained virological response in co-infected patients, the highest ever reported. The treatment did not interfere with the effectiveness of HIV drugs, offering hope for previously untreated patients.
The Yale team will conduct research on implementing structural interventions among high-risk groups in southern India, aiming to reduce HIV transmission and promote healthier behavior. The project, funded by the Bill & Melinda Gates Foundation, aims to address social, economic, and normative factors that contribute to HIV risk.
The HIV Structural Reference Database will aid in developing strategies to inhibit HIV protease activity and understand mutations that make the virus resistant to certain drugs. The database contains annotated structural data from published literature and laboratory contributions.
A mobile testing van was introduced in Zimbabwe's Epworth and Seke areas, offering free rapid HIV tests with same-day results. The initiative reduced structural barriers by providing convenient access to testing and increased acceptance of rapid tests due to same-day results.
A recent study by researchers at the Gladstone Institute of Virology and Immunology investigated potential superinfection involving variations within HIV-1B. The findings, presented at the XV International AIDS Conference, suggest that superinfection may be restricted to a short window period after seroconversion.
Young men in rural Malawi associate HIV with masculinity and engage in risky behavior to demonstrate virility. This misunderstanding of AIDS risk has significant implications for future research and HIV prevention education.
FUZEON shows significant benefits in health improvements and reduced side effects for HIV patients, yet many are missing out due to fear of injection. Physicians and nurses play a pivotal role in educating patients on optimal use of FUZEON.
A study found that gender-and culturally-tailored HIV prevention programs reduced HIV incidence among African American teen girls. The interventions also showed promise in reducing chlamydia cases and promoting healthier relationships.
A study found that rapid HIV testing during labor can provide accurate results within 66 minutes, enabling women to receive antiretroviral prophylaxis. The study also showed higher test acceptance among younger women and those with limited prenatal care, highlighting the importance of early testing for pregnant women.
A randomized trial found that two short drug regimens for infants at birth reduced mother-to-child transmission of HIV compared to a single regimen. The study suggests several options for prevention, including voluntary counseling and testing, standard NVP prophylaxis, and postexposure prophylaxis.
A randomized, controlled clinical trial found that a targeted HIV prevention intervention significantly reduced consistent condom use and risky sexual behaviors in high-risk African-American adolescent girls. The intervention emphasized ethnic and gender pride, HIV knowledge, communication, and healthy relationships.
A randomized trial found that tenofovir disoproxil fumarate achieved high viral load suppression rates, comparable to stavudine-based regimens. Tenofovir DF was also associated with lower toxicity and better lipid profiles.
The Lancet discusses new design changes to the journal, including open-access policies and electronic document posting. The article also explores various HIV/AIDS strategies for developing countries, including expanded access to treatment and prevention efforts. Researchers emphasize the importance of local solutions and community-led ...
The UCSF Center for HIV Information has released the third edition of a CD-ROM targeting healthcare professionals in developing countries. The resource includes 5,000 pages of text on treatments, drugs, and standards of care from various countries.
The Emory Vaccine Center's Hope Clinic will conduct clinical trials for topical vaginal microbicide gels to prevent HIV transmission, particularly among women in Atlanta and worldwide. The trials aim to test the safety and acceptability of two different gel formulations on healthy and high-risk individuals.
Researchers found that APOBEC3F protein can evade VIF's destruction of retroviral restrictors, potentially contributing to HIV resistance. The 'search and destroy' defense of APOBEC proteins may play a crucial role in resisting HIV infection.
Nigerian naval personnel are putting themselves and their partners at risk by denying the existence of AIDS and engaging in risky sexual behaviors. A recent survey found that nearly half of sailors had sex with a female sex worker without using a condom, despite having good knowledge of AIDS-related information.
Researchers found that GBV-C infection slows HIV growth and increases survival in HIV patients. The harmless virus boosts immune proteins, which prevent HIV from infecting cells.
Researchers identified six Lactobacillus strains capable of binding to the HIV envelope, inhibiting infection and potentially blocking transmission. The bacteria also bound to immune cells, causing them to clump and immobilize any infected cells.
Researchers at the Salk Institute have made a breakthrough in understanding how HIV replicates within host cells. The study revealed that molecules exist in cells that help convert HIV's RNA genome to DNA, allowing for the production of new virus particles.
Research has identified improved screening programs for HIV coinfection with chronic hepatitis C, as well as predictive models for inflammation and fibrosis in patients with chronic hepatitis B. These advances aim to improve treatment decisions and quality of life for affected individuals.
A study found that urban American Indian women are at higher risk for contracting HIV due to elevated rates of trauma, including physical and sexual abuse. The research suggests that these women may be exposed to HIV infection despite reports of low risk, highlighting the need for assessments of trauma and prevention measures.
Researchers found that patients taking prednisolone had significantly higher CD4+ T-cell counts after two years compared to those not taking the drug. After five years, over 10% of patients on prednisolone maintained high CD4+ T-cell counts.
Between 1988 and 2000, New York State's HIV prevalence among childbearing women decreased steadily, with a 49% decrease in NYC and a 24% decline statewide. This decline was largely attributed to the widespread use of highly active antiretroviral therapy and targeted efforts aimed at minority populations.
Jay Levy's research has significantly impacted our understanding of HIV and the immune system, leading to major breakthroughs in antiviral responses. His work has also improved the safety of blood products for hemophiliacs and shed light on the role of plasmacytoid dendritic cells in HIV infection.
A South African study found that women experiencing gender-based violence are more likely to contract HIV due to abusive partners imposing risky sexual practices. The research highlights the need for effective interventions to address social constructions of masculinity and intimate partner violence in relation to HIV risk.
Researchers discover HIV mutations that prevent immune system from recognizing protein fragments, allowing virus to replicate and increase in number. This finding highlights the importance of considering nearby regions not recognized by the immune system when designing vaccines.
A study published in Circulation found that HIV infection is an independent predictor of carotid artery intima-media thickness (IMT), which increases the risk of heart attack and stroke. Aggressive treatment of high cholesterol, blood pressure, and other risk factors is crucial for HIV patients.
Researchers found HIV patients had significantly larger carotid IMT and higher rates of plaque build-up compared to uninfected controls. The study suggests HIV infection may be an independent risk factor for atherosclerosis, with lowest CD4 counts associated with thickest artery walls.
Researchers found that dual-infection with HIV and GBV-C leads to better outcomes, including slower progression to AIDS and lower mortality rates. Understanding the mechanism behind this phenomenon could lead to the development of improved therapies.
The study highlights the dangers of crystal methamphetamine use on HIV risk, particularly among young men who have sex with men. Methamphetamine can suppress a part of the immune system important in fighting off HIV, increasing the risk of infection and contracting the disease.
Researchers at Dana-Farber Cancer Institute have identified a protein, TRIM5-alpha, that blocks HIV replication in monkey cells. This discovery opens new avenues for intervening in early HIV infection and provides critical insights into viral uncoating, a little understood step in the viral lifecycle.
A new analysis of FUZEON data found that it does not increase lipodystrophy or glucose levels in pre-treated HIV patients. The treatment also showed a lower incidence of diarrhoea compared to other ARV regimens.
A genetic mutation in the CCR5 gene does not offer protection against HIV infection, according to new research by Scripps scientist Donald Mosier. The study tested the hypothesis that the mutation, which appeared in Europe during the Middle Ages, protected against both HIV and plague.
A multinational trial found that the combination of Pegasys and Copegus significantly increased sustained virological response rates in patients co-infected with HIV and Hepatitis C. The study reported 40% overall efficacy, including 62% efficacy for genotype 2 and 3 patients.
A study found that cities with predominantly black tar heroin use had lower HIV infection rates among injection drug users compared to those using powder heroin. This is due to the properties of black tar heroin, which makes it difficult to transmit HIV through needle sharing.
Researchers found that HIV uses Nef to activate Rac activity in DOCK2ELMO1 complex, disrupting T cell migration and interaction with other lymphocytes. This study provides biochemical evidence for Nef's role in subverting immune response pathways controlled by receptors on T cells.
A study by UCLA researchers found that individuals with shy personalities tend to have higher viral loads and faster disease progression, even on antiretroviral therapy. This suggests that high-stress individuals may be more susceptible to HIV replication due to their heightened nervous system response.
A study found that HIV-positive women are more likely to engage in unprotected sex due to a lack of empowerment or low self-esteem. Ongoing risk-reduction counseling and substance abuse treatment are crucial to curb high-risk behavior, experts say.
The Lancet editorial proposes a serostatus-based approach for universal voluntary knowledge of HIV status, simplified clinical testing, and prevention of discrimination. Two viewpoints discuss the necessity of testing before prophylaxis with single-dose nevirapine in preventing mother-to-child transmission.
A UCSD study of 1,049 HIV-infected children found that specific genetic mutations can affect disease progression and immune system response to the virus. Children with certain polymorphisms, such as CCR5-delta32, showed slower disease progression, while others were more susceptible to worsening symptoms.
The GSK Drug Discovery and Development Research Grant Program awarded $125,000 grants to Paul Bieniasz for genetic screening of cyclic peptides and Michael Farzan for tyrosine-sulfated peptides. Additionally, Michael H. Malim received a grant for his research on the Vif gene, which plays a critical role in HIV infection.
Researchers discovered subtle brain damage in HIV patients taking antiretroviral drugs, despite no apparent symptoms or viral suppression. The study used brainwave recordings, neuropsychological testing, and MRI scans to compare 39 HIV-positive individuals with 35 control subjects.
Researchers found that total lymphocyte count and albumin independently predicted the risk of death in HIV-1-infected children. Using these low-cost measures could establish when to initiate antiretroviral therapy in settings where CD4 and RNA assays are not available.
A study published in AIDS found that placental malaria significantly increases the risk of mother-to-child HIV transmission. The study, which followed 746 HIV-positive mothers and their infants in Rakai, Uganda, suggests that preventing and treating malaria during pregnancy could reduce transmission rates.
The new program combines counseling and education efforts with medical therapy to reduce HIV levels in patients. The initiative aims to assess the impact of integrating prevention services into primary care on HIV risk behaviors and outcomes.
A recent study published by Johns Hopkins Medicine reveals that children with HIV are more likely to visit healthcare providers and receive outpatient care compared to adults. The study found that 90% of HIV-infected children receive antiretroviral medications, highlighting the need for improved access to services.
Patients who view their HIV as an opportunity for personal growth tend to cope better with their disease. Researchers found that more than 73 percent of low-income HIV patients were clinically depressed, highlighting the need for supportive therapy.
A new study found a clear association between genital ulcer symptoms during and after HIV acquisition. Higher rates of genital ulcer disease were observed among HIV-positive participants, particularly those with HSV-2 antibodies.
The European Parliament calls on Eastern European countries to share knowledge and resources to combat HIV resistance. FUZEON, a new treatment, has been shown to reduce HIV levels and increase CD4 cell counts in patients with drug-resistant strains.
Researchers identified a new link in the chain allowing HIV to overcome cellular resistant factor and infect human cells. Disruption of Cul5-SCF function reduces HIV infectiousness by 90%, paving the way for new therapies.
The Emory research team, led by Dr. Frances Priddy and Dr. Mark Feinberg, aims to develop simpler and cheaper monitoring tools for HIV-infected individuals in resource-poor countries. The goal is to enable these individuals to benefit from antiretroviral therapies, which have saved lives in developed countries.
A new study found that forgiving others and feeling forgiven were associated with fewer depressive symptoms, life stressors, and improved quality of life. Expressing forgiveness in the context of HIV infection also decreased the likelihood of placing others at risk.
A study published in The Lancet found that administering nevirapine and zidovudine to babies after birth can significantly reduce mother-to-child HIV transmission. The regimen resulted in a 7% protection rate for infants who received the full course, compared to 12% for those who only received nevirapine.
A study found that administering nevirapine and zidovudine to babies after birth reduced mother-to-child HIV-1 transmission by around 15% compared to nevirapine alone. This combination therapy resulted in a protective efficacy of 36%.
Researchers at OHSU discovered that HIV-encoded protein Vif neutralizes human protein APOBEC3G, which would inactivate HIV if present. This finding could lead to the development of targeted anti-HIV drugs and provide insights into the body's innate protection system.
Four research organizations will receive funding to develop promising HIV vaccine candidates using DNA vaccines, virus vector vaccines, subunit vaccines, and virus-like particle vaccines. Researchers aim to induce strong cellular and antibody immune responses in animal models.
Researchers found that Peptide T significantly reduced HIV levels in cellular reservoirs, with some participants experiencing undetectable virus and increased CD4 counts. The therapy showed promise as a complement or alternative to existing treatments for HIV/AIDS.